BR112012002226A2 - anticorpos muc1. - Google Patents

anticorpos muc1.

Info

Publication number: BR112012002226A2
Authority: BR; Brazil
Prior art keywords: muc1 antibodies; muc1; antibodies
Prior art date: 2009-07-31

Application number

BR112012002226A

Other languages

English (en)

Inventor

Antje Danielczyk

Renate Stahn

Steffen Goletz

Uwe Karsten

Original Assignee

Glycotope Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-31

Filing date

2010-07-30

Publication date

2016-11-08

2010-07-30 Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh

2016-11-08 Publication of BR112012002226A2 publication Critical patent/BR112012002226A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Pulmonology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BR112012002226A 2009-07-31 2010-07-30 anticorpos muc1. BR112012002226A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23021109P	2009-07-31	2009-07-31
EP09009942A EP2281844A1 (en)	2009-07-31	2009-07-31	MUC 1 antibodies
PCT/EP2010/004663 WO2011012309A1 (en)	2009-07-31	2010-07-30	Muc1 antibodies

Publications (1)

Publication Number	Publication Date
BR112012002226A2 true BR112012002226A2 (pt)	2016-11-08

Family

ID=41460131

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112012002226A BR112012002226A2 (pt)	2009-07-31	2010-07-30	anticorpos muc1.

Country Status (17)

Country	Link
US (1)	US9217038B2 (pt)
EP (3)	EP2281844A1 (pt)
JP (2)	JP5922018B2 (pt)
KR (1)	KR101773506B1 (pt)
CN (1)	CN102574926B (pt)
AR (1)	AR077334A1 (pt)
AU (1)	AU2010278302B2 (pt)
BR (1)	BR112012002226A2 (pt)
CA (1)	CA2768888C (pt)
CU (1)	CU23972B1 (pt)
EA (1)	EA029954B1 (pt)
IL (1)	IL217827A (pt)
MX (1)	MX2012000874A (pt)
NZ (1)	NZ597563A (pt)
SG (2)	SG177527A1 (pt)
WO (1)	WO2011012309A1 (pt)
ZA (1)	ZA201200166B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2533964T5 (es)	2006-09-10	2024-05-09	Glycotope Gmbh	Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
EP1920781B1 (en) *	2006-11-10	2015-03-04	Glycotope GmbH	Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
EP2281844A1 (en)	2009-07-31	2011-02-09	Glycotope GmbH	MUC 1 antibodies
US8518405B2 (en)	2009-10-08	2013-08-27	The University Of North Carolina At Charlotte	Tumor specific antibodies and uses therefor
EP2603528B1 (en)	2010-08-10	2016-10-12	Glycotope GmbH	Fab-glycosylated antibodies
US9845362B2 (en)	2010-10-08	2017-12-19	The University Of North Carolina At Charlotte	Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP2748302B1 (en)	2011-08-22	2018-08-15	Glycotope GmbH	Microorganisms carrying a tumor antigen
CN103848890B (zh) *	2012-11-30	2015-09-09	北京市结核病胸部肿瘤研究所	Muc1自身抗体识别的抗原多肽
JP6346604B2 (ja) *	2013-03-01	2018-06-20	学校法人埼玉医科大学	Ｍｕｃ４遺伝子多型を検出することを含む、抗癌剤療法の副作用の発症リスクを判定する方法
US10208125B2 (en) *	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
CA2938819A1 (en) *	2014-02-06	2015-08-13	Medicinal Chemistry Pharmaceuticals, Co., Ltd.	Antibody to mucin 4 (muc4) glycopeptide and uses thereof
RU2016144178A (ru) *	2014-04-28	2018-05-10	Медисинал Кемистри Фармасьютикалс, Ко., Лтд.	Антитело против muc1 или его антигенсвязывающий фрагмент и его применение
WO2016026143A1 (en)	2014-08-22	2016-02-25	Huiru Wang	Saccharide-based biomarkers and therapeutics
US11554181B2 (en)	2014-09-05	2023-01-17	The University Of North Carolina At Charlotte	Tumor specific antibody conjugates and uses therefor
EP3256494A4 (en) *	2015-02-10	2018-12-05	Minerva Biotechnologies Corporation	Humanized anti-muc1* antibodies
WO2017139975A1 (en)	2016-02-19	2017-08-24	Huiru Wang	Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
HUE058689T2 (hu)	2016-11-18	2022-09-28	Astellas Pharma Inc	Új humán MUC1 elleni antitest FAB fragmense
CN112105384A (zh) *	2017-01-18	2020-12-18	苏州启航纳米药物有限公司	癌糖肽的单克隆和人源化抗体
CA3050039A1 (en) *	2017-01-27	2018-08-02	Glycotope Gmbh	Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
CN110382541A (zh)	2017-03-29	2019-10-25	葛莱高托普有限公司	人源化抗cd40抗体
CN110382538A (zh) *	2017-03-29	2019-10-25	葛莱高托普有限公司	结合muc1和cd3的多特异性抗体构建体
US20200148785A1 (en) *	2017-03-29	2020-05-14	Glycotope (GmbH)	Pd-l1 and ta-muc1 antibodies
TWI795415B (zh)	2017-07-07	2023-03-11	日商安斯泰來製藥股份有限公司	新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN117003875A (zh)	2017-09-29	2023-11-07	第一三共株式会社	抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
US11161911B2 (en)	2017-10-23	2021-11-02	Go Therapeutics, Inc.	Anti-glyco-MUC1 antibodies and their uses
MX2020004220A (es) *	2017-10-24	2020-10-05	Go Therapeutics Inc	Anticuerpos anti-glico-muc1 y sus usos.
AU2019226387A1 (en) *	2018-03-01	2020-08-20	Glycotope Gmbh	Fusion protein constructs comprising an anti-MUC1 antibody and IL-15
KR20210011941A (ko) *	2018-05-17	2021-02-02	아스텔라스세이야쿠 가부시키가이샤	항인간 MUC1 항체 Fab 프래그먼트, 펩티드 링커 및/또는 배위자를 포함하는 복합체
JP2021524740A (ja) *	2018-05-18	2021-09-16	グリコトープゲーエムベーハー	抗ｍｕｃ１抗体
CN108982854B (zh) *	2018-06-19	2021-07-27	哈尔滨医科大学	蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
JP2021529524A (ja) *	2018-06-29	2021-11-04	ジーオーセラピューティクス，インコーポレイテッド	抗グリコｍｕｃ１抗体およびその使用
WO2020196474A1 (ja)	2019-03-25	2020-10-01	第一三共株式会社	抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
WO2020196712A1 (ja)	2019-03-27	2020-10-01	第一三共株式会社	抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
WO2023240135A2 (en)	2022-06-07	2023-12-14	Actinium Pharmaceuticals, Inc.	Bifunctional chelators and conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5683674A (en)	1987-01-07	1997-11-04	Imperial Cancer Research Technology Ltd.	Antibody against human mucin core protein and method of preparing and using same
DE69329643T2 (de)	1992-04-13	2001-03-01	Dana Farber Cancer Inst Inc	Gegen karzinom-assoziierte antigene gerichtete antikörper
US5804187A (en)	1992-11-16	1998-09-08	Cancer Research Fund Of Contra Costa	Modified antibodies with human milk fat globule specificity
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US6465220B1 (en)	1998-12-21	2002-10-15	Glycozym Aps	Glycosylation using GalNac-T4 transferase
JP2003519096A (ja)	1999-08-18	2003-06-17	アルタレックスコーポレーション	Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
US7147850B2 (en)	1999-08-18	2006-12-12	Altarex Medical Corp.	Therapeutic binding agents against MUC-1 antigen and methods for their use
GB0029360D0 (en)	2000-12-01	2001-01-17	Univ Nottingham	Humanised antibodies and uses thereof
AU2003266236A1 (en)	2002-07-22	2004-02-09	Nemod Immuntherapie Ag	Method for the production of an immunostimulating mucin (muc1)
AU2003260426A1 (en)	2002-08-16	2004-03-11	Glycotope Gmbh	Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DE10303664A1 (de) *	2003-01-23	2004-08-12	Nemod Immuntherapie Ag	Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
EP1654353B1 (en)	2003-08-18	2013-05-22	Glycotope GmbH	Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
US8609370B2 (en)	2004-02-13	2013-12-17	Glycotope Gmbh	Highly active glycoproteins-process conditions and an efficient method for their production
ES2533964T5 (es)	2006-09-10	2024-05-09	Glycotope Gmbh	Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
EP2281844A1 (en)	2009-07-31	2011-02-09	Glycotope GmbH	MUC 1 antibodies

2009
- 2009-07-31 EP EP09009942A patent/EP2281844A1/en not_active Withdrawn
2010
- 2010-07-28 AR ARP100102737A patent/AR077334A1/es not_active Application Discontinuation
- 2010-07-30 JP JP2012522029A patent/JP5922018B2/ja active Active
- 2010-07-30 EP EP10746999A patent/EP2459595A1/en not_active Withdrawn
- 2010-07-30 SG SG2012000865A patent/SG177527A1/en unknown
- 2010-07-30 AU AU2010278302A patent/AU2010278302B2/en active Active
- 2010-07-30 NZ NZ597563A patent/NZ597563A/xx unknown
- 2010-07-30 EP EP18181262.9A patent/EP3421497A1/en active Pending
- 2010-07-30 KR KR1020127005121A patent/KR101773506B1/ko active IP Right Grant
- 2010-07-30 WO PCT/EP2010/004663 patent/WO2011012309A1/en active Application Filing
- 2010-07-30 US US13/387,587 patent/US9217038B2/en active Active
- 2010-07-30 CA CA2768888A patent/CA2768888C/en active Active
- 2010-07-30 CN CN201080033969.9A patent/CN102574926B/zh active Active
- 2010-07-30 BR BR112012002226A patent/BR112012002226A2/pt not_active Application Discontinuation
- 2010-07-30 MX MX2012000874A patent/MX2012000874A/es active IP Right Grant
- 2010-07-30 SG SG10201404019XA patent/SG10201404019XA/en unknown
- 2010-07-30 EA EA201270207A patent/EA029954B1/ru unknown
2012
- 2012-01-09 ZA ZA2012/00166A patent/ZA201200166B/en unknown
- 2012-01-30 IL IL217827A patent/IL217827A/en active IP Right Grant
- 2012-01-30 CU CU2012000019A patent/CU23972B1/es active IP Right Grant
2016
- 2016-01-04 JP JP2016000133A patent/JP6272916B2/ja active Active

Also Published As

Publication number	Publication date
WO2011012309A8 (en)	2011-04-07
SG10201404019XA (en)	2014-09-26
JP6272916B2 (ja)	2018-01-31
IL217827A (en)	2017-05-29
EP3421497A1 (en)	2019-01-02
CN102574926A (zh)	2012-07-11
EP2281844A1 (en)	2011-02-09
US9217038B2 (en)	2015-12-22
JP5922018B2 (ja)	2016-05-24
US20120128676A1 (en)	2012-05-24
EA201270207A1 (ru)	2012-07-30
IL217827A0 (en)	2012-03-29
CU20120019A7 (es)	2012-06-21
AU2010278302A1 (en)	2012-02-09
JP2016041771A (ja)	2016-03-31
WO2011012309A1 (en)	2011-02-03
CA2768888C (en)	2019-02-26
ZA201200166B (en)	2013-03-27
CA2768888A1 (en)	2011-02-03
AU2010278302B2 (en)	2014-12-18
JP2013500703A (ja)	2013-01-10
EA029954B1 (ru)	2018-06-29
CN102574926B (zh)	2014-10-15
CU23972B1 (es)	2013-12-27
KR101773506B1 (ko)	2017-08-31
SG177527A1 (en)	2012-02-28
MX2012000874A (es)	2012-02-01
KR20120051724A (ko)	2012-05-22
NZ597563A (en)	2013-08-30
AR077334A1 (es)	2011-08-17
EP2459595A1 (en)	2012-06-06

Legal Events

Date	Code	Title	Description
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-05-05	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-08-18	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-08-24	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-12-07	B09B	Patent application refused [chapter 9.2 patent gazette]
2022-02-08	B12B	Appeal against refusal [chapter 12.2 patent gazette]

Publication	Publication Date	Title
BR112012002226A2 (pt)	2016-11-08	anticorpos muc1.
BRPI1011005A2 (pt)	2018-03-06	anticorpos anti-epcam
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
BRPI1010297A2 (pt)	2017-06-06	anticorpos biespecíficos trivalentes.
BRPI1010301A2 (pt)	2016-03-15	composição.
BRPI1006166A2 (pt)	2016-02-23	gestos padrão.
BR112012000281A2 (pt)	2016-08-09	proteína quimérica.
DK2930184T3 (da)	2019-05-13	Dkk-1-antistoffer
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
IT1396487B1 (it)	2012-12-14	Convogliatore.
DK2442870T3 (da)	2014-06-30	Pyrazinooxazepin-derivater.
BRPI1016192A2 (pt)	2016-04-19	derivados de soxazol.
BRPI1008708A2 (pt)	2016-03-08	gastroscópio.
BRPI1011794A2 (pt)	2018-02-27	compartimento.
BR112012002612A2 (pt)	2018-03-13	calha.
BRPI0912769A2 (pt)	2015-10-13	anticorpos anti-pirb
BRPI0815733A2 (pt)	2015-02-10	Estrutura flutuante.
IT1394801B1 (it)	2012-07-13	Struttura di lampada.
IT1394901B1 (it)	2012-07-20	Struttura di lampada.
IT1396642B1 (it)	2012-12-14	Statore.
BR112012000911A2 (pt)	2016-11-22	biomarcador.
BRPI1009515A2 (pt)	2015-08-18	Complexos de proteínas/glicosinolatos eletrostáticos.
BRPI1007503A2 (pt)	2016-02-16	refletor acústico.
IT1401345B1 (it)	2013-07-18	Bomboletta.
FR2946591B1 (fr)	2012-12-28	Sur-tapis eclairant.